Detalhe da pesquisa
1.
IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH.
Hepatology
; 77(1): 20-32, 2023 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35686937
2.
Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate.
J Lipid Res
; 64(3): 100339, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36737040
3.
NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learned.
J Hepatol
; 78(4): 852-865, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36526000
4.
Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD.
Hepatology
; 76(6): 1811-1824, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-35561146
5.
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
J Hepatol
; 77(3): 607-618, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35439567
6.
A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis.
Hepatology
; 73(3): 1105-1116, 2021 03.
Artigo
Inglês
| MEDLINE | ID: mdl-32745270
7.
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.
Hepatology
; 72(1): 58-71, 2020 07.
Artigo
Inglês
| MEDLINE | ID: mdl-32115759
8.
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
Hepatology
; 70(3): 788-801, 2019 09.
Artigo
Inglês
| MEDLINE | ID: mdl-30661255
9.
Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells.
Am J Physiol Endocrinol Metab
; 306(2): E150-6, 2014 Jan 15.
Artigo
Inglês
| MEDLINE | ID: mdl-24253050
10.
Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes.
Proc Natl Acad Sci U S A
; 108(22): E159-68, 2011 May 31.
Artigo
Inglês
| MEDLINE | ID: mdl-21536911
11.
Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers.
Clin Transl Sci
; 16(3): 536-547, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36573450
12.
Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist.
J Clin Pharmacol
; 63(9): 1017-1025, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37128693
13.
AI-based histologic scoring enables automated and reproducible assessment of enrollment criteria and endpoints in NASH clinical trials.
medRxiv
; 2023 Apr 25.
Artigo
Inglês
| MEDLINE | ID: mdl-37162870
14.
Semi-Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA.
Clin Pharmacol Ther
; 111(2): 416-424, 2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34623640
15.
Phenoxyacetic acids as PPARδ partial agonists: synthesis, optimization, and in vivo efficacy.
Bioorg Med Chem Lett
; 21(8): 2345-50, 2011 Apr 15.
Artigo
Inglês
| MEDLINE | ID: mdl-21414782
16.
Glucose sensing by MondoA:Mlx complexes: a role for hexokinases and direct regulation of thioredoxin-interacting protein expression.
Proc Natl Acad Sci U S A
; 105(19): 6912-7, 2008 May 13.
Artigo
Inglês
| MEDLINE | ID: mdl-18458340
17.
Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors.
Sci Transl Med
; 13(616): eabe8939, 2021 Oct 20.
Artigo
Inglês
| MEDLINE | ID: mdl-34669440
18.
Identification and characterization of a selective peroxisome proliferator-activated receptor beta/delta (NR1C2) antagonist.
Mol Endocrinol
; 22(2): 523-9, 2008 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-17975020
19.
Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms.
Carcinogenesis
; 29(1): 169-76, 2008 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-17893232
20.
The next generation of PPAR drugs: do we have the tools to find them?
Biochim Biophys Acta
; 1771(8): 1082-93, 2007 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-17602866